Randomized control trial of oral arginine therapy for children with sickle cell anemia hospitalized for pain in Nigeria

Richard Onalo, Peter Cooper, Antoinette Cilliers, Barend C Vorster, Nnebe-Agumadu Uche, Oniyangi O Oluseyi, Victoria D Onalo, Yunusa Zubairu, Alice U Ayodele-Kehinde, Oladimeji M Damilare, Janet Figueroa, Claudia R Morris, Richard Onalo, Peter Cooper, Antoinette Cilliers, Barend C Vorster, Nnebe-Agumadu Uche, Oniyangi O Oluseyi, Victoria D Onalo, Yunusa Zubairu, Alice U Ayodele-Kehinde, Oladimeji M Damilare, Janet Figueroa, Claudia R Morris

Abstract

Low arginine bioavailability is associated with vaso-occlusive painful crisis (VOC) severity in sickle cell anemia (SCA) and predicts need for pediatric hospitalization. Intravenous arginine therapy has opioid-sparing effects and was found to significantly decrease pain scores in children hospitalized with SCA-VOC in a phase-two randomized placebo-controlled trial (RCT). Efficacy of oral arginine is unknown. Our objective was to determine the safety and efficacy of oral arginine therapy in Nigerian children with SCA. A double-blind RCT of oral L-arginine-hydrochloride (100 mg/kg TID) was conducted in children with SCA-VOC, aged 5-17 years, hospitalized at two Nigerian sites. The primary outcome measure was analgesic usage, quantified by difference in the mean Analgesic Medication Quantification Scale (MQS). Secondary outcomes included daily pain scores, time-to-crisis-resolution and length-of-hospital-stay. An intention-to-treat analysis was performed. Sixty-eight children (age 5-17 years, mean 10.6 ± 0.4 years; 56% male), were randomized to receive L-arginine (35 patients) or placebo (33 patients). The mean total MQS for the arginine group was 73.4 (95% CI, 62.4-84.3) vs 120.0 (96.7-143.3) for placebo (P < .001). The mean rate of decline in worst pain scores was faster in the arginine arm vs placebo (1.50 [1.23-1.77] vs 1.09 [0.94-1.24] point/d, P = .009). Children receiving arginine had a shorter time-to-crisis-resolution (P = .02), shorter hospital-stay (P = .002) and experienced no serious adverse event. Pain control was more rapid, total analgesic requirement was significantly reduced, and most notably, time-to-crisis-resolution and length-of-hospital-stay were shorter in children with SCA-VOC receiving arginine vs placebo. Given the established safety and low cost, oral arginine is a promising adjuvant therapy for SCA-VOC management.

© 2020 Wiley Periodicals LLC.

References

REFERENCES

    1. Piel FB, Patil AP, Howes RE, et al. Global distribution of the sickle cell gene and geographical confirmation of the malaria hypothesis. Nat Commun. 2010;1:104.
    1. Centers for Disease Prevention and Control. Centers for Disease Prevention and Control Web site. . Accessed October 31, 2020.
    1. Aygun B, Odame I. A global perspective on sickle cell disease. Pediatr Blood Cancer. 2012;59(2):386-390.
    1. Grosse SD, Odame I, Atrash HK, Amendah DD, Piel FB, Williams TN. Sickle cell disease in Africa: a neglected cause of early childhood mortality. Am J Prev Med. 2011;41(6 suppl 4):S398-S405.
    1. Muoghalu C. Sickle cell disease child mortality - a silent epidemic in Nigeria: issues in political economy. Blood Res Transfus J. 2018;2(2):1-3.
    1. Brousseau DC, Owens PL, Mosso AL, Panepinto JA, Steiner CA. Acute care utilization and rehospitalizations for sickle cell disease. JAMA. 2010;303(13):1288-1294.
    1. Hoppe C, Styles L, Vichinsky E. The natural history of sickle cell disease. Curr Opin Pediatr. 1998;10(1):49-52.
    1. Lanzkron S, Carroll CP, Haywood C Jr. The burden of emergency department use for sickle-cell disease: an analysis of the national emergency department sample database. Am J Hematol. 2010;85(10):797-799.
    1. Yusuf HR, Atrash HK, Grosse SD, Parker CS, Grant AM. Emergency department visits made by patients with sickle cell disease: a descriptive study, 1999-2007. Am J Prev Med. 2010;38(4 suppl):S536-S541.
    1. Yawn BP, Buchanan GR, Afenyi-Annan AN, et al. Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members. JAMA. 2014;312(10):1033-1048.
    1. Carden MA, Brousseau DC, Ahmad FA, et al. Normal saline bolus use in pediatric emergency departments is associated with poorer pain control in children with sickle cell anemia and vaso-occlusive pain. Am J Hematol. 2019;94(6):689-696.
    1. Carden MA, Patil P, Ahmad ME, Lam WA, Joiner CH, Morris CR. Variations in pediatric emergency medicine physician practices for intravenous fluid management in children with sickle cell disease and vaso-occlusive pain: a single institution experience. Pediatr Blood Cancer. 2018;65(1). .
    1. Morris SM Jr. Regulation of arginine availability and its impact on NO synthesis. In: Ignarro L, ed. Nitric Oxide. Biology and Pathobiology. San Diego: Academic Press; 2000:187-197.
    1. Morris CR, Hamilton-Reeves J, Martindale RG, Sarav M, Ochoa Gautier JB. Acquired amino acid deficiencies: a focus on arginine and glutamine. Nutr Clin Pract. 2017;32(1_suppl):30S-47S.
    1. Dembele KC, Veyrat-Durebex C, Aldiouma G, et al. Sickle cell disease: metabolomic profiles of vaso-occlusive crisis in plasma and erythrocytes. J Clin Med. 2020;9(4).1092. .
    1. Kato GJ, Steinberg MH, Gladwin MT. Intravascular hemolysis and the pathophysiology of sickle cell disease. J Clin Invest. 2017;127(3):750-760.
    1. Morris CR, Kato GJ, Poljakovic M, et al. Dysregulated arginine metabolism, hemolysis-associated pulmonary hypertension and mortality in sickle cell disease. JAMA. 2005;294:81-90.
    1. Morris CR, Morris SM Jr, Hagar W, et al. Arginine therapy: a new treatment for pulmonary hypertension in sickle cell disease? Am J Respir Crit Care Med. 2003;168:63-69.
    1. Cox SE, Makani J, Komba AN, et al. Global arginine bioavailability in Tanzanian sickle cell anaemia patients at steady-state: a nested case control study of deaths versus survivors. Br J Haematol. 2011;155(4):522-524.
    1. Morris CR, Kuypers FA, Larkin S, Vichinsky E, Styles L. Patterns of arginine and nitric oxide in sickle cell disease patients with vaso-occlusive crisis and acute chest syndrome. J Pediatr Hematol Oncol. 2000;22:515-520.
    1. Lopez B, Kreshak A, Morris CR, Davis-Moon L, Ballas S, Ma X. L-arginine levels are diminished in adult acute vaso-occlusive sickle cell crisis in the emergency department. Br J Haematol. 2003;120:532-534.
    1. Morris CR, Kuypers FA, Lavrisha L, et al. A randomized, placebo-controlled trial of arginine therapy for the treatment of children with sickle cell disease hospitalized with vaso-occlusive pain episodes. Haematologica. 2013;98(9):1375-1382.
    1. Morris CR, Kuypers FA, Larkin S, et al. Arginine therapy: a novel strategy to increase nitric oxide production in sickle cell disease. Br J Haematol. 2000;111:498-500.
    1. Jacob E, Miaskowski C, Savedra M, Beyer JE, Treadwell M, Styles L. Quantification of analgesic use in children with sickle cell disease. Clin J Pain. 2007;23(1):8-14.
    1. Morris C, Figueroa J, Watt A, et al. Safety of intravenous arginine therapy in children with sickle cell disease hospitalized for vaso-occlusive pain: a randomized placebo-controlled trial in progress. Blood. 2019;134:995.
    1. Cox SE, Ellins EA, Marealle AI, et al. Ready-to-use food supplement, with or without arginine and citrulline, with daily chloroquine in Tanzanian children with sickle-cell disease: a double-blind, random order crossover trial. Lancet Haematol. 2018;5(4):e147-e160.
    1. Marealle AI, Siervo M, Wassel S, et al. A pilot study of a non-invasive oral nitrate stable isotopic method suggests that arginine and citrulline supplementation increases whole-body NO production in Tanzanian children with sickle cell disease. Nitric Oxide. 2018;74:19-22.
    1. Harima A, Shimizu H, Takagi H. Analgesic effect of L-arginine in patients with persistent pain. Eur Neuropsychopharmacol. 1991;1(4):529-533.
    1. Kawabata A, Nishimura Y, Takagi H. L-leucyl-L-arginine, naltrindole and D-arginine block antinociception elicited by L-arginine in mice with carrageenin-induced hyperalgesia. Br J Pharmacol. 1992;107(4):1096-1101.
    1. Morris CR, Vichinsky EP, van Warmerdam J, et al. Hydroxyurea and arginine therapy: impact on nitric oxide production in sickle cell disease. J Pediatr Hematol Oncol. 2003;25:629-634.
    1. Morris CR, Brown LA, Reynolds M, et al. Impact of arginine therapy on mitochondrial function in children with sickle cell disease during vaso-occlusive pain. Blood. 2020;136(12):1402-1406.
    1. Bortolotti M, Brunelli F, Sarti P, Miglioli M. Clinical and manometric effects of L-arginine in patients with chest pain and oesophageal motor disorders. Ital J Gastroenterol Hepatol. 1997;29(4):320-324.
    1. Black P, Max MB, Desjardins P, Norwood T, Ardia A, Pallotta T. A randomized, double-blind, placebo-controlled comparison of the analgesic efficacy, onset of action, and tolerability of ibuprofen arginate and ibuprofen in postoperative dental pain. Clin Ther. 2002;24(7):1072-1089.
    1. Desjardins P, Black P, Papageorge M, et al. Ibuprofen arginate provides effective relief from postoperative dental pain with a more rapid onset of action than ibuprofen. Eur J Clin Pharmacol. 2002;58(6):387-394.
    1. Little JA, Hauser KP, Martyr SE, et al. Hematologic, biochemical, and cardiopulmonary effects of L-arginine supplementation or phosphodiesterase 5 inhibition in patients with sickle cell disease who are on hydroxyurea therapy. Eur J Haematol. 2009;82(4):315-321.
    1. McMahon L, Tamary H, Askin M, et al. A randomized phase II trial of arginine butyrate with standard local therapy in refractory sickle cell leg ulcers. Br J Haematol. 2010;151(5):516-524.
    1. Yeo TW, Lampah DA, Rooslamiati I, et al. A randomized pilot study of L-arginine infusion in severe falciparum malaria: preliminary safety, efficacy and pharmacokinetics. PLoS One. 2013;8(7):e69587.
    1. Lopansri BK, Anstey NM, Weinberg JB, et al. Low plasma arginine concentrations in children with cerebral malaria and decreased nitric oxide production. Lancet. 2003;361(9358):676-678.
    1. Dirajlal-Fargo S, Alam K, Sattar A, et al. Comprehensive assessment of the arginine pathway and its relationship to inflammation in HIV. AIDS. 2017;31(4):533-537.
    1. Omodeo-Sale F, Cortelezzi L, Vommaro Z, Scaccabarozzi D, Dondorp AM. Dysregulation of L-arginine metabolism and bioavailability associated to free plasma heme. Am J Physiol Cell Physiol. 2010;299(1):C148-C154.
    1. Yeo TW, Rooslamiati I, Gitawati R, et al. Pharmacokinetics of L-arginine in adults with moderately severe malaria. Antimicrob Agents Chemother. 2008;52(12):4381-4387.
    1. Yeo TW, Lampah DA, Gitawati R, et al. Recovery of endothelial function in severe falciparum malaria: relationship with improvement in plasma L-arginine and blood lactate concentrations. J Infect Dis. 2008;198(4):602-608.
    1. Yeo TW, Lampah DA, Gitawati R, et al. Safety profile of L-arginine infusion in moderately severe falciparum malaria. PLoS One. 2008;3(6):e2347.
    1. Dasgupta T, Hebbel RP, Kaul DK. Protective effect of arginine on oxidative stress in transgenic sickle mouse models. Free Radic Biol Med. 2006;41(12):1771-1780.
    1. Oyedeji GA. Socio-economic and cultural background of hospitalized children in Ilesha. Niger J Paediatr. 1985;12:111-117.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi